International Journal of Cancer Management

Published by: Kowsar

A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran

Roham Salek 1 , Fatemeh Varshoee Tabrizi 2 , Kamran Ghaffarzadegan 3 , Golnaz Sabouri 4 and Azar Fanipakdel 1 , *
Authors Information
1 Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Reza Radiation Oncology Center, Mashhad, Iran
3 Pathology Department, Razavi Hospital, Mashhad, Iran
4 Clinical Governance Department, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Iranian Journal of Cancer Prevention: January 2017, 10 (1); e4371
  • Published Online: January 18, 2017
  • Article Type: Research Article
  • Received: November 14, 2015
  • Revised: February 1, 2016
  • Accepted: January 3, 2017
  • DOI: 10.17795/ijcp-4371

To Cite: Salek R, Varshoee Tabrizi F, Ghaffarzadegan K, Sabouri G, Fanipakdel A. A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran, Int J Cancer Manag. 2017 ; 10(1):e4371. doi: 10.17795/ijcp-4371.

Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. WHO. . Iranian annual of national cancer registration report, 2005-2006.
  • 2. Ferlay J, Shin HR, Bray F. Cancer incidence and mortality worldwide, international agency for research on cancer. 2010;
  • 3. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J. 2009; 15(6): 1426-31[PubMed]
  • 4. Sharifian A, Pourhoseingholi MA, Emadedin M, Rostami Nejad M, Ashtari S, Hajizadeh N, et al. Burden of Breast Cancer in Iranian Women is Increasing. Asian Pac J Cancer Prev. 2015; 16(12): 5049-52[PubMed]
  • 5. Gianni B, Gabriel NH, Pinuccia V. Textbook of breast cancer aclinical guide to therapy. 2006; : 86
  • 6. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27(27): 4515-21[DOI][PubMed]
  • 7. Rakha E, Reis-Filho JS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med. 2009; 133(6): 860-8[DOI][PubMed]
  • 8. Katrina RB, Monica B, Rosemary DC, Carol AP, Vincent C. Descriptive analysis of estrogen receptor (er)- negative, progesterone receptor (pr)- negative, and her2- negative invasive breast cancer, the so- called triple- negative phenotype. Cancer. 2007;
  • 9. Francesca R, Sandra B, Amalia F, Angelo M, Camilla C, Romeo B, et al. Triple-negative breast cancer:current state of the art. Tumori. 2010; 96: 875-88
  • 10. Nielsen TO. Immunohistochemical and clinical characterization of basal- like subtype of invasive breast carcinoma. Clinical Cancer Res. 2004; : 5367-74
  • 11. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26(15): 2568-81[DOI][PubMed]
  • 12. Rubovszky G, Udvarhelyi N, Horvath Z, Lang I, Kasler M. [Triple-negative breast carcinoma--rewiev of current literature]. Magy Onkol. 2010; 54(4): 325-35[DOI][PubMed]
  • 13. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008; 15(4): 303-8[DOI][PubMed]
  • 14. Mise M, Higashide S, Hashimoto K, Kawada K, Hanaki K, Kanda Y, et al. [Clinicopathological features of young patients with triple negative breast cancer]. Gan To Kagaku Ryoho. 2009; 36(10): 1677-81[PubMed]
  • 15. Gerson R, Alban F, Villalobos A, Serrano A. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype]. Gac Med Mex. 2008; 144(1): 27-34[PubMed]
  • 16. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113(2): 357-70[DOI][PubMed]
  • 17. Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, et al. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat. 2010; 123(1): 177-87[DOI][PubMed]
  • 18. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007; 14(6): 419-30[DOI][PubMed]
  • 19. Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A, Normanno N. Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit Rev Eukaryot Gene Expr. 2010; 20(1): 17-34[PubMed]
  • 20. Lee JH, Kim SH, Suh YJ, Shim BY, Kim HK. Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. Cancer Res Treat. 2010; 42(1): 30-6[DOI][PubMed]
  • 21. Koo JS, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J. 2011; 52(1): 89-97[DOI][PubMed]
  • 22. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008; 52(1): 108-18[DOI][PubMed]
  • 23. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19(2): 264-71[DOI][PubMed]
  • 24. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7: 134[DOI][PubMed]
  • 25. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14(5): 1368-76[DOI][PubMed]
  • 26. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005; 447(4): 688-94[DOI][PubMed]
  • 27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9): 1217-26[DOI][PubMed]
  • 28. Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007; 67(2): 501-10[DOI][PubMed]
  • 29. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11(14): 5175-80[DOI][PubMed]
  • 30. Koronakis N, Karanikas G, Lagoudianakis EE, Grosomanidis D, Pappas A, Chrysikos J, et al. Analysis of clinical and molecular associations of triple negative breast cancers in node-negative patients. Eur J Gynaecol Oncol. 2010; 31(3): 304-7[PubMed]
  • 31. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2007; 60(9): 1006-12[DOI][PubMed]
  • 32. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363(20): 1938-48[DOI][PubMed]
  • 33. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008; 14(5): 456-63[DOI][PubMed]
  • 34. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009; 153(1): 13-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments